According to Altimmune's latest financial reports the company's current revenue (TTM) is $0.42 M. In 2022 the company made a revenue of -$0.07 M a decrease over the years 2021 revenue that were of $4.41 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.42 M | -726.47% |
2022 | -$0.07 M | -101.54% |
2021 | $4.41 M | -46.11% |
2020 | $8.18 M | 41.09% |
2019 | $5.8 M | -67.88% |
2018 | $18.05 M | 43412.15% |
2017 | $0.04 M | -98.19% |
2016 | $2.28 M | -78.49% |
2015 | $10.64 M | 4.42% |
2014 | $10.19 M | -43.11% |
2013 | $17.91 M | -28.85% |
2012 | $25.17 M | 3.75% |
2011 | $24.26 M | 15.59% |
2010 | $20.99 M | -23.8% |
2009 | $27.54 M | -16.29% |
2008 | $32.91 M | 126.16% |
2007 | $14.55 M | 966.24% |
2006 | $1.36 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
OPKO Health
OPK | $0.86 B | 202,598.12% | ๐บ๐ธ USA |
Onconova Therapeutics ONTX | $0.22 M | -46.95% | ๐บ๐ธ USA |